Is Drug Chemical And Associated Technologies Association Inc Legit?

Drug Chemical And Associated Technologies Association Inc (DCAT) demonstrates a generally healthy financial position with consistent revenue growth over the past several years, culminating in $5,604,025 in revenue for the 202310 period. The organization consistently operates with a surplus, as evidenced by its 202310 expenses of $4,288,341 against its revenue, indicating sound financial management. Its asset base has also shown significant growth, reaching $7,492,601 in 202310, suggesting a strong financial foundation. Spending efficiency appears reasonable, with expenses consistently lower than revenue, allowing for asset accumulation. The absence of reported officer compensation across all available filings suggests either a volunteer-led executive structure or compensation is reported under other expense categories, which could impact the perception of transparency regarding leadership costs. Further detail on functional expenses would be needed for a precise assessment of program versus administrative spending efficiency. Overall, DCAT appears to be a financially stable organization with a positive trend in revenue and assets. The lack of reported officer compensation is a notable point for transparency, as it can obscure the full cost of leadership. However, the consistent surpluses and asset growth indicate prudent financial stewardship.